Revenue has shown a steady year-over-year increase from approximately $222.6 billion in FY 2025 to $254.2 billion in FY 2026, reflecting a growth rate near 14%. Quarterly revenues have increased consistently across the last four quarters, affirming stable top-line performance. Operating income remains positive but with thin margins, showing slight compression relative to previous years.

Revenue growth is predominantly driven by volume increases in pharmaceutical distribution and a growing healthcare services segment. The relatively flat gross profit margins around 3.8%-4.3% highlight pricing pressures and higher cost bases that are typical for the distribution industry.

Gross margin has improved marginally from about 3.3%-3.7% last year to just over 4.3% recently, indicating some operational leverage or cost efficiencies. However, EBITDA and operating margins remain subdued at approximately 1.4%-1.7% and 1.1% respectively, reflecting high operating expenses and cost of goods sold.

Earnings quality appears solid, with net income ratio steadily around 0.6%-0.7%. The company has managed interest expenses well, maintaining moderate debt levels. No significant non-recurring charges or write-offs are evident, underscoring recurring earnings derived mainly from core operations.

CAH experienced approximately 14% YoY revenue growth from FY 2025 to FY 2026, with quarterly revenue increasing from about $54.9 billion in early 2025 to over $63.8 billion in Q2 2026. This growth is consistent, though recent quarters show a slight moderation compared to prior rates.

EPS has improved substantially from about $3.48 in FY 2024 to $7.27 in FY 2026, driven by operational improvements and better cost controls. The latest quarter EPS of $2.91 exceeded estimates, continuing a positive earnings growth trajectory.

Primary drivers include expanded pharmaceutical distribution volumes, value-added logistics services, and efficiency gains from technology integration in supply chain management.

Growth is primarily organic, driven by core distribution capabilities and scaling of healthcare services. There is limited indication of acquisitive growth, enhancing the sustainability and reliability of expansion.

Gross margins have inched upwards from roughly 3.3% to above 4.3%, while EBITDA margins remained under 2%, reflecting cost pressures. Operating margins hover near 1.1%, indicating tight profitability but positive operating leverage on incremental sales.

Precise ROE and ROA data are unavailable, but net income ratios around 0.6%-0.7% suggest modest returns in line with large distribution sector norms. The incremental margin improvement supports stable, if not robust, returns.

Sustainability is plausible given the company's scale and operational improvements, but margin expansion may be capped by intense competition and industry pricing dynamics.